Enhanced O-linked Glcnacylation in Crohn's disease promotes intestinal inflammation.
Crohn's disease (CD)
NF-κB
O-Linked β-N-acetylglucosamine (O-GlcNAc)
UDP-N-acetylglucosamine (UDP-GlcNAc)
adherent-invasive Escherichia coli (AIEC) LF82
inflammatory bowel disease
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
15
01
2020
accepted:
12
02
2020
pubmed:
3
3
2020
medline:
18
12
2020
entrez:
2
3
2020
Statut:
ppublish
Résumé
Treatment of Crohn's disease (CD) remains to be a challenge due to limited insights for its pathogenesis. We aimed to determine the role of O-Linked β-N-acetylglucosamine (O-GlcNAc) in the development of CD and evaluate therapeutic effects of O-GlcNAc inhibitors on CD. O-GlcNAc in intestinal epithelial tissues of CD, adherent-invasive Escherichia coli (AIEC) LF82-infected cells and mice was determined by immunoblot and immunohistochemistry. AIEC LF82 and dextran sulfate sodium were administrated into C57BL/6 mice for estabolishing inflammatory bowel disease model and for therapeutic study. O-GlcNAc was increased in intestinal epithelial tissues of CD patients and AIEC LF82-infected mice. Infection of AIEC LF82 up-regulated the level of UDP-GlcNAc and increased O-GlcNAc in human colon epithelial HCT116 and HT-29 cells. We identified that IKKβ and NF-κB were O-Glycosylated in AIEC LF82-treated cells. Mutations of IKKβ (S733A) and p65 (T352A) abrogated the O-GlcNAc in IKKβ and NF-κB and inhibited AIEC LF82-induced activation of NF-κB. Application of 6-diazO-5-oxO-L-norleucine, an agent that blocks the production of UDP-GlcNAc and inhibits O-GlcNAc, inactivated NF-κB in AIEC LF82-infected cells, enhanced the formation of autophagy, promoted the removal of cell-associated AIEC LF82, alleviated intestinal epithelial inflammation, and improved the survival of the colitis mice. Intestinal inflammation in CD is associated with increased O-GlcNAc modification, which is required for NF-κB activation and suppression of autophagy. Targeting O-GlcNAc could be an effective therapy for inflammatory bowel disease. National Natural Science Foundation of China (Nos. 81573087 and 81772924) and International Cooperation Foundation of Jilin Province (20190701006GH).
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of Crohn's disease (CD) remains to be a challenge due to limited insights for its pathogenesis. We aimed to determine the role of O-Linked β-N-acetylglucosamine (O-GlcNAc) in the development of CD and evaluate therapeutic effects of O-GlcNAc inhibitors on CD.
METHODS
METHODS
O-GlcNAc in intestinal epithelial tissues of CD, adherent-invasive Escherichia coli (AIEC) LF82-infected cells and mice was determined by immunoblot and immunohistochemistry. AIEC LF82 and dextran sulfate sodium were administrated into C57BL/6 mice for estabolishing inflammatory bowel disease model and for therapeutic study.
FINDINGS
RESULTS
O-GlcNAc was increased in intestinal epithelial tissues of CD patients and AIEC LF82-infected mice. Infection of AIEC LF82 up-regulated the level of UDP-GlcNAc and increased O-GlcNAc in human colon epithelial HCT116 and HT-29 cells. We identified that IKKβ and NF-κB were O-Glycosylated in AIEC LF82-treated cells. Mutations of IKKβ (S733A) and p65 (T352A) abrogated the O-GlcNAc in IKKβ and NF-κB and inhibited AIEC LF82-induced activation of NF-κB. Application of 6-diazO-5-oxO-L-norleucine, an agent that blocks the production of UDP-GlcNAc and inhibits O-GlcNAc, inactivated NF-κB in AIEC LF82-infected cells, enhanced the formation of autophagy, promoted the removal of cell-associated AIEC LF82, alleviated intestinal epithelial inflammation, and improved the survival of the colitis mice.
INTERPRETATION
CONCLUSIONS
Intestinal inflammation in CD is associated with increased O-GlcNAc modification, which is required for NF-κB activation and suppression of autophagy. Targeting O-GlcNAc could be an effective therapy for inflammatory bowel disease.
FUNDING
BACKGROUND
National Natural Science Foundation of China (Nos. 81573087 and 81772924) and International Cooperation Foundation of Jilin Province (20190701006GH).
Identifiants
pubmed: 32114385
pii: S2352-3964(20)30068-2
doi: 10.1016/j.ebiom.2020.102693
pmc: PMC7047186
pii:
doi:
Substances chimiques
NF-kappa B
0
Acetylglucosamine
V956696549
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102693Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have declared that no competing of interest exists.
Références
J Clin Invest. 2007 Jun;117(6):1566-74
pubmed: 17525800
Nat Cell Biol. 2007 Feb;9(2):218-24
pubmed: 17237771
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
J Biol Chem. 2003 Apr 4;278(14):12294-304
pubmed: 12540841
J Exp Med. 2017 Feb;214(2):401-422
pubmed: 28082357
Cell Immunol. 2012 Jul-Aug;278(1-2):1-9
pubmed: 23121969
J Biol Chem. 1985 Jan 10;260(1):139-46
pubmed: 3965444
Gastroenterology. 2014 Jan;146(1):188-99
pubmed: 24036151
Annu Rev Biochem. 2012;81:451-78
pubmed: 22663080
Clin Exp Immunol. 2018 Apr;192(1):129-137
pubmed: 29247492
Cell Mol Gastroenterol Hepatol. 2015 Mar 1;1(2):154-170
pubmed: 26000334
BMC Microbiol. 2009 Aug 26;9:180
pubmed: 19709415
J Biol Chem. 1998 Feb 6;273(6):3611-7
pubmed: 9452489
Transl Gastrointest Cancer. 2013 Jan 1;2(1):21-29
pubmed: 23626930
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16888-93
pubmed: 23027940
Biochim Biophys Acta. 2013 Nov;1833(11):2438-46
pubmed: 23434682
Cell Host Microbe. 2018 Dec 12;24(6):791-803.e6
pubmed: 30543776
BMC Res Notes. 2014 Oct 22;7:748
pubmed: 25338542
J Exp Med. 2017 Apr 3;214(4):1093-1109
pubmed: 28280036
Sci Signal. 2013 Aug 27;6(290):ra75
pubmed: 23982206
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3431-6
pubmed: 19202066
Nat Rev Mol Cell Biol. 2017 Jul;18(7):452-465
pubmed: 28488703
Diabetes. 1995 Dec;44(12):1438-46
pubmed: 7589852
Nat Rev Mol Cell Biol. 2012 Apr 23;13(5):312-21
pubmed: 22522719
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
EMBO Mol Med. 2018 Aug;10(8):
pubmed: 29941542
Antimicrob Agents Chemother. 2009 Jun;53(6):2306-11
pubmed: 19349513
Nat Med. 2012 Jul;18(7):1052-9
pubmed: 22683778
Cell. 2014 Oct 9;159(2):306-17
pubmed: 25303527
PLoS Pathog. 2013 Jan;9(1):e1003141
pubmed: 23358328
N Engl J Med. 2002 Aug 8;347(6):417-29
pubmed: 12167685
Oncotarget. 2015 May 20;6(14):12529-42
pubmed: 25915426
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9333-8
pubmed: 27482104
Gastroenterology. 2004 Aug;127(2):412-21
pubmed: 15300573
J Biol Chem. 2019 Feb 15;294(7):2211-2231
pubmed: 30626734
J Bioenerg Biomembr. 2018 Jun;50(3):231-240
pubmed: 29671171
Glycobiology. 2016 Jan;26(1):13-8
pubmed: 26369908
Gastroenterology. 2010 Oct;139(4):1147-55
pubmed: 20637205
Infect Immun. 2006 Aug;74(8):4778-92
pubmed: 16861666
Microbiology (Reading). 2014 Jun;160(Pt 6):1020-1039
pubmed: 24705229